PMID- 31015751
OWN - NLM
STAT- MEDLINE
DCOM- 20191125
LR  - 20191125
IS  - 0386-300X (Print)
IS  - 0386-300X (Linking)
VI  - 73
IP  - 2
DP  - 2019 Apr
TI  - Salvage Haploidentical Transplantation Using Low-dose ATG for Early Disease 
      Relapse after First Allogeneic Transplantation: A Retrospective Single-center 
      Review.
PG  - 161-171
LID - 10.18926/AMO/56652 [doi]
AB  - Second allogeneic stem cell transplantation (allo-SCT) is a potentially curative 
      therapy for patients who relapse after first allo-SCT. Human leukocyte antigen 
      (HLA)-haploidentical related donors provide the broad opportunity to conduct 
      second SCT at the appropriate time, but the efficacy of second SCT from 
      haploidentical donors after relapse has not been established. We retrospectively 
      analyzed the records of 33 patients who underwent second SCT. Twenty patients 
      underwent haplo-SCT with low-dose antithymocyte globulin (ATG), and the other 13 
      patients underwent conventional- SCTs, including HLA-matched related peripheral 
      blood, unrelated bone marrow or cord blood. Three years after the second SCT, the 
      overall survival (OS) and progression-free survival (PFS) of all patients were 
      32.5% and 23.9%. Multivariate analyses indicated that non-complete response at 
      second SCT, less than 1-year interval to relapse after first- SCT, and total 
      score >/= 3 on the hematopoietic cell transplantation-specific comorbidity index 
      were significantly associated with a lower PFS rate. The haplo- and conventional- 
      SCT groups showed equivalent results regarding OS, PFS, cumulative incidences of 
      relapse, non-relapse mortality and graft-versus-host disease. The neutropenic 
      period after transplantation was significantly shorter in haplo- SCT than 
      conventional- SCT (10.5 days vs. 16 days, p=0.001). Our analysis revealed that 
      haplo-SCT could be an alternative therapeutic option for relapsed patients after 
      first SCT.
FAU - Okamoto, Sachiyo
AU  - Okamoto S
AD  - Department of Hematology and Oncology, Okayama University Graduate School of 
      Medicine, Dentistry and Pharmaceuticals Sciences, Okayama 700-8558, Japan.
FAU - Matsuoka, Ken-Ichi
AU  - Matsuoka KI
FAU - Sakamoto, Maiko
AU  - Sakamoto M
FAU - Usui, Yoshiaki
AU  - Usui Y
FAU - Fujiwara, Yuki
AU  - Fujiwara Y
FAU - Kondo, Takumi
AU  - Kondo T
FAU - Tani, Katsuma
AU  - Tani K
FAU - Saeki, Kyosuke
AU  - Saeki K
FAU - Meguri, Yusuke
AU  - Meguri Y
FAU - Asada, Noboru
AU  - Asada N
FAU - Ennishi, Daisuke
AU  - Ennishi D
FAU - Nishimori, Hisakazu
AU  - Nishimori H
FAU - Fujii, Keiko
AU  - Fujii K
FAU - Fujii, Nobuharu
AU  - Fujii N
FAU - Maeda, Yoshinobu
AU  - Maeda Y
LA  - eng
PT  - Journal Article
PL  - Japan
TA  - Acta Med Okayama
JT  - Acta medica Okayama
JID - 0417611
RN  - 0 (HLA Antigens)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Case-Control Studies
MH  - Female
MH  - Graft vs Host Disease/etiology/prevention & control
MH  - HLA Antigens/genetics
MH  - Hematopoietic Stem Cell Transplantation/adverse effects/*methods/mortality
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Progression-Free Survival
MH  - Recurrence
MH  - Retrospective Studies
MH  - Salvage Therapy/*methods
MH  - Treatment Outcome
MH  - Young Adult
OTO - NOTNLM
OT  - allogeneic stem cell transplantation
OT  - anti-T lymphocyte globulin
OT  - haploidentical stem cell transplantation
OT  - relapse
COIS- No potential conflict of interest relevant to this article was reported.
EDAT- 2019/04/25 06:00
MHDA- 2019/11/26 06:00
CRDT- 2019/04/25 06:00
PHST- 2019/04/25 06:00 [entrez]
PHST- 2019/04/25 06:00 [pubmed]
PHST- 2019/11/26 06:00 [medline]
AID - 10.18926/AMO/56652 [doi]
PST - ppublish
SO  - Acta Med Okayama. 2019 Apr;73(2):161-171. doi: 10.18926/AMO/56652.